UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000035121
Receipt number R000039806
Scientific Title Efficacy and Safety of Ruxolitinib single treatment in patients with chronic active Epstein-Barr virus infection (Phase II) (investigator-initiated study)
Date of disclosure of the study information 2018/12/15
Last modified on 2022/12/05 11:10:06

No. Disposal Last modified on Item of update
1 Insert 2018/12/03 17:55:51
2 Update 2018/12/25 16:04:15 Anticipated trial start date
3 Update 2019/01/09 11:26:34 Recruitment status
Anticipated trial start date
4 Update 2019/02/08 16:28:30 Institutions
5 Update 2019/04/16 14:08:56 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Zip code
Address
Address
TEL

Last name of contact person

Last name of contact person
Organization
Organization
Division name
Division name
Zip code
Address
Address
TEL
Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Name of primary person or sponsor
Institute
Organization
Organization
Address
Address
Tel
Email
6 Update 2019/04/16 14:15:52 Date of IRB
Last follow-up date
7 Update 2019/04/16 14:20:24 Key inclusion criteria
Key inclusion criteria
8 Update 2019/04/16 15:26:35 UMIN ID2
9 Update 2019/04/16 15:56:02 Division name
10 Update 2019/06/13 13:26:35 UMIN ID1
11 Update 2019/06/13 15:30:11 Organization1
Address1
Tel1
Email1
Organization
Organization
Address
Address
Tel
Email
12 Update 2020/12/17 16:06:13 UMIN ID2
13 Update 2021/01/12 08:59:35 UMIN ID1
14 Update 2021/01/13 15:45:34 UMIN ID2
15 Update 2021/01/18 15:34:57
Last name of contact person

Last name of contact person
Name of person sending information
Name of person sending information
Institutions
16 Update 2021/06/04 18:48:51 Last follow-up date
17 Update 2021/09/01 20:09:48 Recruitment status
18 Update 2021/09/01 20:23:56 Number of participants that the trial has enrolled
19 Update 2022/06/07 09:19:33 Email
Email
20 Update 2022/06/07 09:27:34 Division name
Division name
21 Update 2022/12/05 11:10:06 Recruitment status